BLCM Bellicum Pharmaceuticals Inc

EQUITY ALERT: Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against Bellicum Pharmaceuticals, Inc. – BLCM

Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Bellicum Pharmaceuticals, Inc. (NASDAQ: BLCM) from May 8, 2017 through January 30, 2018, inclusive (the “Class Period”). The lawsuit seeks to recover damages for Bellicum investors under the federal securities laws.

To join the Bellicum class action, go to http://rosenlegal.com/cases-1286.html or call Phillip Kim, Esq. or Daniel Sadeh, Esq. toll-free at 866-767-3653 or email [email protected] or [email protected] for information on the class action.

NO CLASS HAS YET BEEN CERTIFIED IN THE ABOVE ACTION. UNTIL A CLASS IS CERTIFIED, YOU ARE NOT REPRESENTED BY COUNSEL UNLESS YOU RETAIN ONE. YOU MAY ALSO REMAIN AN ABSENT CLASS MEMBER AND DO NOTHING AT THIS POINT. YOU MAY RETAIN COUNSEL OF YOUR CHOICE.

According to the lawsuit, defendants during the Class Period made materially false and/or misleading statements and/or failed to disclose that: (1) a substantial undisclosed risk of encephalopathy was associated with Bellicum’s lead product candidate, BPX-501; and (2) as a result, Bellicum’s public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than April 9, 2018. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. If you wish to join the litigation, go to http://rosenlegal.com/cases-1286.html or to discuss your rights or interests regarding this class action, please contact Phillip Kim, Esq. or Daniel Sadeh, Esq. of Rosen Law Firm toll free at 866-767-3653 or via e-mail at [email protected] or [email protected].

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm or on Twitter: https://twitter.com/rosen_firm.

Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Since 2014, Rosen Law Firm has been ranked #2 in the nation by Institutional Shareholder Services for the number of securities class action settlements annually obtained for investors.

EN
06/02/2018

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Bellicum Pharmaceuticals Inc

 PRESS RELEASE

Bellicum Discontinues Phase 1/2 Trials and Initiates Evaluation of Str...

Bellicum Discontinues Phase 1/2 Trials and Initiates Evaluation of Strategic Alternatives HOUSTON, March 14, 2023 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (Nasdaq: BLCM), today announced its decision to discontinue its ongoing Phase 1/2 clinical trials evaluating the safety and preliminary efficacy of its GoCAR-T cell product candidates in combination with rimiducid in heavily pre-treated cancer patients. The trials for BPX-601 and BPX-603 are being discontinued following the Company’s assessment of the risk/benefit profile of BPX-601 in combination with rimiducid. The most rec...

 PRESS RELEASE

Bellicum Presents Early Phase 1 Results for BPX-601 in Prostate Cancer...

Bellicum Presents Early Phase 1 Results for BPX-601 in Prostate Cancer at ASCO GU Cancers Symposium Biochemical and radiographic responses reported in first two cohorts of dose escalation in heavily pre-treated metastatic castration-resistant prostate cancer (mCRPC) patients PSA50 or greater responses in 50% of patients Responses observed in patients with visceral, nodal and bone involvement HOUSTON, Feb. 16, 2023 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today will present early Ph...

 PRESS RELEASE

CORRECTION -- Bellicum Reports Inducement Grants Under Nasdaq Listing ...

CORRECTION -- Bellicum Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) HOUSTON, Jan. 31, 2023 (GLOBE NEWSWIRE) -- In a release issued earlier today by Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), please note that the total number of stock options should be 20,000, not 45,000, as previously stated. The corrected release follows: Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced equity inducement grants to 1 new employee consisting of an aggregate of 20,000 stock options. The Compen...

 PRESS RELEASE

Bellicum Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4...

Bellicum Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) HOUSTON, Jan. 31, 2023 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced equity inducement grants to 1 new employee consisting of an aggregate of 45,000 stock options. The Compensation Committee of the Board of Directors approved the grants with an effective date of January 31, 2023. The stock options were granted as inducements material to the employees entering into employment with the Company in accordan...

 PRESS RELEASE

Bellicum Pharmaceuticals to Present Early Phase 1 Results for BPX-601 ...

Bellicum Pharmaceuticals to Present Early Phase 1 Results for BPX-601 in Prostate Cancer at ASCO 2023 Genitourinary Cancers Symposium HOUSTON, Jan. 19, 2023 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (Nasdaq: BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced that an abstract on early results from a Phase 1 clinical trial for BPX-601, its lead GoCAR-T® product candidate, has been accepted for poster presentation at the 2023 American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU). The meeting is being held...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch